Indication: newly diagnosed or recurrent; combo with active agents
Title: Glioblastoma (newly diagnosed or recurrent; combo with active agents) | XPORT-GBM-029
Drug: selinexor

Please visit clinicaltrials.gov for more information about this study

This trial is for selinexor.

Phase 1Phase 2Phase 3Commercial
Phase 1
Phase 2
Phase 3
Commercial